(IBD) Northern Lights Fund Trust - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US1416376036 • Corporate Bond

IBD: Corporate Bonds, Investment Grade Securities

The Northern Lights Fund Trust IV - Inspire Corporate Bond Impact ETF (NYSE ARCA: IBD) is an exchange-traded fund designed to provide exposure to large-capitalization, investment-grade corporate bonds issued by companies with strong ESG performance. The fund invests at least 80% of its total assets in securities that compose its underlying index, which is selected based on a combination of financial and ESG criteria.

The funds index provider identifies eligible securities as domestic corporate bonds issued by large-cap companies that meet specific investment-grade ratings from recognized bond rating agencies. Additionally, these bonds must have an Inspire Impact Score of zero or higher, indicating alignment with ESG principles. This dual focus aims to balance financial returns with positive societal impact.

From a technical standpoint, IBD has shown a stable price trend, with its 20-day, 50-day, and 200-day moving averages converging closely around the $23.50 mark. The Average True Range (ATR) of 0.17 indicates low volatility, suggesting modest price fluctuations. The funds average trading volume of approximately 200,000 shares over the past 20 days reflects moderate liquidity.

Over the next three months, based on and , IBD is expected to maintain its stable performance. The funds moving averages suggest continued price convergence, and the low ATR supports a forecast of sideways trading with minimal volatility. The funds assets under management (AUM) of $365.14 million provide a solid foundation for liquidity and stability. Overall, IBD is anticipated to deliver consistent returns in line with its investment-grade portfolio.

Additional Sources for IBD ETF

IBD ETF Overview

Market Cap in USD 388m
Category Corporate Bond
TER 0.44%
IPO / Inception 2017-07-10

IBD ETF Ratings

Growth Rating 13.5
Fundamental -
Dividend Rating 72.5
Rel. Strength 5.14
Analysts -
Fair Price Momentum 23.09 USD
Fair Price DCF -

IBD Dividends

Dividend Yield 12m 4.27%
Yield on Cost 5y 4.49%
Annual Growth 5y 17.72%
Payout Consistency 93.0%

IBD Growth Ratios

Growth Correlation 3m 44%
Growth Correlation 12m 76.5%
Growth Correlation 5y -18.6%
CAGR 5y 1.16%
CAGR/Max DD 5y 0.08
Sharpe Ratio 12m 2.49
Alpha 1.47
Beta -0.015
Volatility 7.01%
Current Volume 79.3k
Average Volume 20d 50.9k
What is the price of IBD stocks?
As of May 09, 2025, the stock is trading at USD 23.60 with a total of 79,304 shares traded.
Over the past week, the price has changed by -0.51%, over one month by +1.50%, over three months by +1.08% and over the past year by +5.57%.
Is Northern Lights Fund Trust a good stock to buy?
Neither. Based on ValueRay Analyses, Northern Lights Fund Trust is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 13.48 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IBD as of May 2025 is 23.09. This means that IBD is currently overvalued and has a potential downside of -2.16%.
Is IBD a buy, sell or hold?
Northern Lights Fund Trust has no consensus analysts rating.
What are the forecast for IBD stock price target?
According to ValueRays Forecast Model, IBD Northern Lights Fund Trust will be worth about 24.9 in May 2026. The stock is currently trading at 23.60. This means that the stock has a potential upside of +5.68%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 24.9 5.7%